- News Home
6 March 2014 1:04 pm ,
Vol. 343 ,
Antiretroviral drugs can protect people from becoming infected by HIV. But so-called pre-exposure prophylaxis, or PrEP...
Two studies show that eating a diet low in protein and high in carbohydrates is linked to a longer, healthier life, and...
Considered an icon of conservation science, researchers at World Wildlife Fund (WWF) headquarters in Washington, D.C.,...
The new atlas, which shows the distribution of important trace metals and other substances, is the first product of...
Early in April, the first of a fleet of environmental monitoring satellites will lift off from Europe's spaceport in...
Since 2000, U.S. government health research agencies have spent almost $1 billion on an effort to churn out thousands...
Magdalena Koziol, a former postdoc at Yale University, was the victim of scientific sabotage. Now, she is suing the...
- 6 March 2014 1:04 pm , Vol. 343 , #6175
- About Us
Immunologist Takes Scalpel to Merck R&D
1 October 2013 3:00 pm
Immunologist Roger Perlmutter is shaking things up again at Merck. After eliminating a corps of managers in June, the newly anointed Merck R&D chief is now following through on the “major surgery” that he promised in an interview in The Wall Street Journal last month. The drug giant will cut 8500 more jobs as part of its ongoing overhaul. The layoffs, amounting to roughly 20% of the workforce, are intended to cut operating expenses by $2.5 billion by the end of 2015, the company announced today in a press release.
Merck CEO Kenneth Frazier explained today in The Wall Street Journal that the firm aims to rebound from recent failures and devote more resources to the company’s most promising efforts, including cancer immunotherapy and diabetes research.